Skip to main content
OpenTrials
Completed

NCT Number: NCT05246072

Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients

The aim of this study will be to investigate the efficacy of use of combination of Ivermectin and colchicine on severity and outcome Of COVID 19 infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ain Shams University hospitals

Cairo, 11591, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide written informed consent prior to performing study procedures.
  • Currently hospitalized and requiring medical care for non-sever COVID-19.
  • One or more of the following: (positive PCR test or positive antibodies) or (CT Chest consistent with COVID19 infection).

Exclusion criteria

  • Tocilizumab use.
  • Mechanical ventilation
  • Requirement of oxygen supplementation >8L/min on admission

Treatment and study plan

Ivermectin + colchicine

Drug

In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine

Colchicine

Drug

In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine

Primary outcomes

  1. length of oxygen requirement

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Feb 18, 2022
Registry last updated
Apr 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.